Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

EMPACTA
 
NCT04372186
RCTtocilizumab placeboCOVID 19 hospitalizedsome concern
259/129 conclusif
  • demonstrated 44 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 45 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
NCT04412772 (ARCHITECTS) unpublished
 
NCT04412772
RCTtocilizumab placeboCOVID 19 hospitalizedlow
10/11 inconclusive

    COVID 19 all comers meta-analysis

    BACC Bay Tocilizumab Trial
     
    NCT04356937
    RCTtocilizumab placeboCOVID 19 all comerslow
    161/81 inconclusive
    • inconclusive 17 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias

    COVID-19 severe or critically meta-analysis

    Rosas (REMDACTA)
     
    NCT04409262
    RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
    434/215 inconclusive
    • inconclusive 3 % decrease in hospital discharge (PE) with a moderate degree of certainty due to some concern in risk of bias
    COVACTA (Rosas)
     
    NCT04320615
    RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
    301/151 suggested
    • inconclusive 19 % increase in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    1 study excluded by filtering options (1 RCT / 0 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).